Nutriband Inc. (NTRB) Stock

Nutriband Inc. (NTRB) is a Healthcare stock trading at $3.80 (as of 2026-08-20), with a market capitalization of $46.19M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Nutriband Inc. develops transdermal pharmaceutical products, including an abuse-deterrent fentanyl transdermal system (AVERSA fentanyl) and other candidates such as AVERSA buprenorphine and AVERSA methylphenidate, along with exenatide for type 2 diabetes and follicle stimulating hormone for infertility. The company also holds a license agreement with Rambam Med-Tech Ltd. for development of RAMBAM Closed System Transfer Devices.

Understand Nutriband Inc.: how it makes money

Nutriband Inc. develops transdermal pharmaceutical products (like AVERSA fentanyl for chronic pain) and makes money, if its pipeline is successful, by commercializing these drug candidates for clinical and patient use.

The profit model is tied to advancing and successfully commercializing its transdermal drug development pipeline, since the core business is product development rather than an existing operating line-by-line revenue stream.

Business quality (Weak): Clear view of the product pipeline, but no reportable segments and no operational KPIs were provided, so the company's near-term operating drivers are hard to track beyond the reported loss profile.

Bull case

Pipeline breadth across multiple therapeutic areas: Beyond its lead program, AVERSA fentanyl, Nutriband also develops AVERSA buprenorphine and AVERSA methylphenidate, plus exenatide for type 2 diabetes and follicle stimulating hormone for infertility.
Lead product targets an important opioid use case: AVERSA fentanyl is described as an abuse-deterrent fentanyl transdermal system intended for clinicians and patients managing chronic pain requiring around-the-clock opioid therapy.
Partner licensing support: The company has a license agreement with Rambam Med-Tech Ltd. for its transdermal fentanyl and buprenorphine products (text provided is truncated, but the existence of the license is stated).

Bear case

Deep operating losses in the latest period: The latest reported operating margin is -289.4%, indicating substantial operating losses.
No clear evidence of meaningful current revenue generation: The provided revenue for the latest period is 0.0B, which limits visibility into how much of the business is already monetized.
Dependence on development outcomes: Most disclosed products are described as in development, which increases uncertainty around timing, regulatory outcomes, and commercial adoption.

Valuation — source: SEC EDGAR (first-party)
Price	$3.80
Market Cap	$46.19M
Price / Book	7.71
Price / Sales	25.63
FCF Yield	-15.3%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$2.04M
Net Margin	-404.1%
Revenue Growth (YoY)	-35.1%
EPS Growth (YoY)	-16.7%

Financial Health — source: SEC EDGAR
Altman Z-Score	-11.36 (distress)

Valuation vs Sector & Industry
Sector P/E (Healthcare)	21.6
Industry P/E (Medical Equipment)	32.9

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	VANGUARD GROUP INC ($920431.00)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Medical Equipment
CEO	Gareth Sheridan
Employees	13
Country	US
IPO Date	2021-10-01

Related Companies (Business model: Medical Devices / Life Science Tools; 8 closest by market cap; US-domiciled)

Data as of 2026-08-20.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.